Focused Ultrasound Therapy
Focused ultrasound is an early-stage, non-invasive, therapeutic technology with the potential to improve the quality of life and decrease the cost of care for patients with soft tissue tumors. This novel technology focuses beams of ultrasonic energy precisely and accurately on targets deep in the body without damaging surrounding normal tissue. Where the beams converge, the ultrasound produces precise ablation (thermal destruction of tissue) enabling soft tissue tumors to be treated without surgery.
The primary options for treatment of soft tissue tumors include surgery with possible chemotherapy or radiation. For certain patients, focused ultrasound could provide a non-invasive alternative to surgery with less risk of complications and lower cost.
Primary Soft Tissue Tumors
The primary (intrinsic to the soft tissue) tumors can be benign or malignant. Most of the research with benign tumors had been done with desmoid tumors, which are benign but aggressive tumors that have been treated with focused ultrasound on some anecdotal cases with good results. (See “Desmoid Tumors” for more information.)
There are a variety of malignant soft tissue tumors including multiple types of sarcomas and other connective tissue diseases. There are clinical trials (listed below) for refractory or relapsed malignant tumors.
There has been some work on Actinic Keratosis, Basal Cell Carcinoma and other dermatologic conditions by a company in Denmark called Toosonix.
Secondary Soft Tissue Tumors
The secondary tumors that are found in the soft tissue most commonly come from the skin, lung, breast, kidney, colon and rectum. These malignancies are becoming the target in clinical trials, particularly in the pediatric and young adult population.
- Focused ultrasound is non-invasive, so it does not carry added concerns like surgical wound healing or infection.
- In some uses, there is an enhanced chemotherapeutic dose for the target, with less impact on the rest of the patient.
- Focused ultrasound is radiation free.
- It can be repeated, if necessary.
A clinical trial at the University of Texas Southwestern Medical Center is looking at the use of focused ultrasound to create hyperthermia in combination with lysosomal doxorubicin will be helpful in pediatric and young adult patients with solid tumors, including soft tissue tumors.
A clinical trial at the Children’s National Medical Center, in Washington, D.C. is currently enrolling children and young adult patients who have a wide variety of relapsed or refractory tumors for ablative therapy.
A clinical trial at the Children’s National Medical Center, in Washington, D.C. is currently enrolling children and young adult patients who have a wide variety of relapsed or refractory tumors for a combination of liposomal doxorubicin and focused ultrasound therapy.
Regulatory & Reimbursement
The Model JC Haifu system has received regulatory approval in Europe, Russia, and China for treatment of soft tissue tumors, including sarcomas. At present, focused ultrasound is not universally reimbursed for treatment of soft tissue sarcomas.
Several organizations worldwide support patients with soft tissue sarcomas. Among them are:
Desmoid Tumor Research Foundation, which encourages you to join the DTRF Patient Registry in order to facilitate research efforts. With access to your experience as a patient, researchers will be able to continue learning and making new discoveries in the field of desmoid tumors. If you have ever had a desmoid tumor, you can participate. For more information, visit http://dtrf.org/.
Sarcoma Alliance, which works to improve the lives of patients affected by sarcomas through better diagnostic accuracy, improved access to care, education, and support. For more information, visit www.sarcomaalliance.org.
Sarcoma Patients Euronet, which works with clinical experts, research scientists, industry, and others to improve treatment and care for sarcoma patients in Europe by increasing awareness and providing patients with support and information. For more information, visit www.sarcoma-patients.eu.
Agnese V, Costa V, Scoarughi GL, Corso C, Carina V, De Luca A, Bellavia D, Raimondi L, Pagani S, Midiri M, Stassi G, Alessandro R, Fini M, Barbato G, Giavaresi G. Focused Ultrasound Effects on Osteosarcoma Cell Lines. Biomed Res Int. 2019 May 19;2019:6082304. doi: 10.1155/2019/6082304. eCollection 2019.
Ghanouni P, Dobrotwir A, Bazzocchi A, Bucknor M, Bitton R, Rosenberg J, Telischak K, Busacca M, Ferrari S, Albisinni U, Walters S, Gold G, Ganjoo K, Napoli A, Pauly KB, Avedian R. Magnetic resonance-guided focused ultrasound treatment of extra-abdominal desmoid tumors: a retrospective multicenter study. Eur Radiol. 2017 Feb;27(2):732-740. doi: 10.1007/s00330-016-4376-5.
Shim J, Staruch RM, Koral K, Xie XJ, Chopra R, Laetsch TW. Pediatric Sarcomas Are Targetable by MR-Guided High Intensity Focused Ultrasound (MR-HIFU): Anatomical Distribution and Radiological Characteristics. Pediatr Blood Cancer. 2016 Oct;63(10):1753-60. doi: 10.1002/pbc.26079.
Avedian RS, Bitton R, Gold G, Butts-Pauly K, Ghanouni P. Is MR-guided High-intensity Focused Ultrasound a Feasible Treatment Modality for Desmoid Tumors? Clin Orthop Relat Res. 2016 Mar;474(3):697-704. doi: 10.1007/s11999-015-4364-0.
Ghanouni P, Butts Pauly K, Bitton R, Avedian R, Bucknor M,Gold G. MR guided focused ultrasound treatment of soft tissue tumors of the extremities — preliminary experience. J Ther Ultrasound. 2015; 3(Suppl 1): O69.
Click here for additional references from PubMed.